查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太地區 AI 輔助醫學影像市場
市場調查報告書
商品編碼
1796156

亞太地區 AI 輔助醫學影像市場

APAC AI-assisted Medical Imaging Market
出版日期: | 出版商: Marketstrat, Inc. | 英文 102 Pages | 訂單完成後即時交付

價格

報告元資料

  • 研究方法與品質保證：雙重視角（自上而下的漏斗模型 + 自下而上的獲取率引擎），記錄的品質保證循環（協調、監管差距、證據新鮮度、ASP 健康狀況）。
  • 格式 PDF（分析師評論、圖表和國家細分）。

目標範圍

  • 檢查方式（CT、MRI、X 光/DR、超音波、PET/核子醫學）；
  • 臨床領域（腫瘤科、神經內科/中風、心臟科、呼吸/肺科、MSK/骨科、全科）；
  • 應用（提高診斷準確性和分類、效率和數據處理（工作流程）、早期檢測和異常、預後和治療（準確性）、影像增強和劑量優化、分割和特徵提取、跨模態整合）；
  • 收入來源（硬體、軟體、服務、雲端/按使用付費）；
  • 最終用途（醫院、診斷影像中心、診所、遠距放射科、其他）；
  • 人工智慧技術（深度學習、電腦視覺、機器學習、自然語言處理、機器人技術、專家系統）。
  • 預測（2023-2032）：中國、日本、印度、韓國、澳洲及世界其他地區（亞太地區）

內容（僅限亞太地區的框架和工具）

  • GTM 成長與成熟度 - 亞太地區供應商地圖、監管速度、汽車製造商 AI 安裝率、GTM 準備就緒雷達以及國家/地區層面的格局和時間表（中國、日本、印度、韓國、澳新銀行、亞太地區）。

為何撰寫本報告？

亞太地區是 AI 影像處理領域成長最快的地區，複合年增長率約為 31%，從 2023 年的 6.1 億美元增長至 2032 年的 73 億美元，並將在未來十年內超越歐洲。買家需要針對特定區域的證據、連接階梯以及針對特定國家的GTM工具，才能從試點走向規模化。這份 "脈搏報告" 以區域為重點，提供了這些內容。

購買指南

  • 影像設備原始設備製造商 (OEM)、PACS/VNA 和雲端供應商正在建造亞太地區的捆綁包和投標方案。
  • 純人工智慧廠商正在針對中國、印度、東協、日本/韓國和紐西蘭在地化模組和定價。
  • 供應商網路（醫院集團、遠端影像中心）計畫推出企業級 "AI 商店" 。
  • 投資者和通路夥伴正在仔細審查證據、監管速度和GTM成熟度。

買方利益

  • 1.根據國家/地區和細分市場評估投資機會，並結合與附加率假設相關的可靠數據（CT - 新增單位的 10%，MR - 8%，DR - 6% 基準年）。
  • 2.使用區域框架（GTM 的成長和成熟度、監管狀態、GTM 準備）和特定國家/地區的分層格局/時間表，確定優先發展領域。
  • 3.使用監管和採購清單（NMPA、PMDA、MFDS、TGA、HSA、CDSCO）、雲端/資料駐留提示和定價原型（許可證 vs. 按使用付費）來實現市場在地化。
  • 4.降低定價和部署風險，結合實際情況提供資料（OEM 與純廠商的佔有率劃分、改裝佔有率、組裝率階梯），並預測未來 12 個月的快速行動。
  • 5. 證據和品質保證 (QA) 準備 - 所有表格和分割都經過記錄在案的品質保證 (QA) 循環，我們引用了亞太模型中使用的證據堆疊。

概覽與要點

  • 亞太地區成長趨勢：6.1 億美元至 73 億美元（2023-2032 年），複合年增長率為 31%，到 2032 年，亞太地區在全球市場的佔有率將接近 30%。
  • 收入集中度：CT/MR 將維持核心地位，印度/東協的 POCUS 超音波和低頻段 DR 將成為最快的單位規模驅動力，PET/核子醫學將從腫瘤治療診斷領域發展壯大。
  • 臨床引擎：到 2032 年，腫瘤學、神經病學（中風）和心臟病學將佔絕對增長的 75%。
  • 收入結構變化：軟體 + 雲端/按使用付費將快速擴張（日本/韓國/澳新地區為企業套件，印度/東協地區為按研究付費）。
  • 依從性基線：CT 約為 10% → 隨著 OEM 捆綁包的增加而增加，MR 約為 8%，DR 約為 6%。
  • 12 個月預期： 在各市場（NMPA/PMDA/MFDS/TGA/HSA/CDSCO）的頂級模組申請、本地雲預驗證（數據駐留）、AI 偵察 + 卒中分診（日本/韓國/澳新）以及 DR 胸腔/超聲心動圖 AI 按研究（印度/東盟）方面領先。

研究方法與品質保證

此預測將亞太地區自上而下的總數與全球匯總資料以及自下而上的按模式（出貨量、安裝基數升級、工廠與改裝附件、本地 ASP 頻段）的附件率流程進行比較。亞太地區模型由監管線（NMPA/PMDA/MFDS/TGA/HAS/CDSCO）、印度 ABDM 數位健康軌道以及同行評審的 RWE 提供支援。四個品質保證循環用於檢查國家/模式協調差異（小於 0.5%）、監管計數差異、證據新鮮度以及平均服務提供者 (ASP) 健康狀況。

目錄

章節1-摘要整理

章節2-調查手法

章節3-亞太地區(亞太地區)市場

  • 規模、發展軌跡與戰略重要性
  • 需求推動因素與不利因素
  • 競爭與合作格局
  • 策略集群與市場進入細微差別
  • 策略建議
  • 法規/政策（新功能或說明）
  • 亞太地區 AI 成像市場（按國家/地區劃分）
  • Markintel GTM 成長與成熟度矩陣 -亞太地區
  • 併購觀察名單 - 亞太地區
  • 監管速度 - 亞太地區
  • 汽車廠商 AI 採用率 - 亞太地區
  • GTM 概覽 - 亞太地區
  • 亞太地區快速策略提示

章節4-中國市場

  • 中國 - 市場概覽與策略摘要 (2023-2032)
  • 策略要點
  • 中國市場預測 (2023-2032)
  • Markintel 成長成熟度矩陣 - 中國醫學影像 AI
  • Markintel 生態系協作矩陣 - 中國
  • Markintel 解採用率與成長矩陣 - 中國
  • GTM 概覽 - 中國

章節5-日本市場

  • 市場概覽與策略摘要：日本
  • 戰略展望
  • 行動要點
  • 日本市場預測 (2023-2032)
  • Markintel 解採用率與成長矩陣 - 日本
  • Markintel 生態系協作矩陣 - 日本
  • 市場進入 (GTM) 策略 - 日本

章節6-印度市場

  • 市場概覽與分析
  • 市場機制
  • 阻礙因素圖
  • 競爭溫度
  • 可操作機會 (2024-2026)
  • 未來建議（依參與者類型）
  • 定義成功
  • 印度市場預測 (2023-2032)
  • Markintel 解採用率與成長矩陣 - 印度
  • Markintel 生態系協作矩陣 - 印度
  • 競爭格局 -印度
  • GTM 概覽 - 印度

章節7-韓國市場

  • 市場總結與概況：韓國
  • 韓國市場預測 (2023-2032)
  • GTM 概覽 - 韓國

章節8-澳洲市場

  • 市場概覽與分析
  • 市場結構與成長動力
  • 細分市場熱點（定性分析）
  • 競爭格局
  • 策略影響與 GTM 優先事項
  • 行動導向建議（未來 12 個月）
  • 澳洲市場預測 (2023-2032)
  • GTM 概覽 - 澳大利亞

第9章 -其他的亞太地區市場

  • 市場概覽與分析
  • 亞太其他地區市場預測 (2023-2032)
  • GTM 概覽 - 亞太其他地區
Product Code: MINTP-M01122

Report Metadata

  • Methodology & QA: Dual lens (top down funnel + bottom up attach rate engine) with a documented QA loop (reconciliation, regulatory diffs, evidence freshness, ASP sanity).
  • Format: PDF (analyst narrative, charts, country breakouts).

Scope

  • Modalities (CT, MRI, X ray/DR, Ultrasound, PET/Nuclear);
  • Clinical areas (Oncology, Neurology/Stroke, Cardiology, Respiratory/Lung, MSK/Ortho, General);
  • Applications (Improved Diagnostic Accuracy & Classification, Efficiency & Data Handling (Workflow), Early Detection & Abnormality, Prognosis & Treatment (Precision), Image Enhancement & Dose Optimization, Segmentation & Feature Extraction, Integration Across Modalities);
  • Revenue streams (Hardware, Software, Service, Cloud/Pay per Use);
  • End use (Hospitals, Imaging Centers, Clinics, Teleradiology, Other);
  • AI Technology (Deep Learning, Computer Vision, Machine Learning, NLP, Robotics, Expert Systems).
  • Forecasts (2023-2032): China, Japan, India, South Korea, Australia, Rest of Asia-Pacific (ROAPAC)

What's inside (APAC only frameworks & tools)

  • GTM Growth & Maturity - APAC vendor map; Regulatory Velocity; OEM AI Attach Rate; GTM Readiness Radar; Country tiered landscapes & timelines (China, Japan, India, South Korea, ANZ, ROAPAC).

Why This Report

APAC is the fastest growing region in AI imaging, moving from ~US$0.61B (2023) to ~US$7.3B (2032) -about 31% CAGR-and overtakes Europe before decade end. Buyers need region specific evidence, attach rate ladders, and country GTM tools to move from pilots to scale; this Pulse report delivers exactly that, in one region focused volume.

Who Should Buy

  • Imaging OEMs, PACS/VNA and cloud vendors building APAC bundles and tenders
  • AI pure plays localizing modules and pricing for China, India, ASEAN, Japan/Korea, and ANZ
  • Provider networks (hospital groups, teleradiology hubs) planning enterprise "AI store" rollouts
  • Investors and channel partners vetting evidence, regulatory velocity and GTM maturity

Buyer Benefits

  • 1. Size the opportunity by country and segment with defendable numbers tied to attach rate assumptions (CT ~10% of new units; MR ~8%; DR ~6% base year).
  • 2. Prioritize where to play using regional frameworks (GTM Growth & Maturity, Regulatory Velocity, GTM Readiness) and country tiered landscapes/timelines.
  • 3. Localize go to market with regulatory and procurement checklists (NMPA, PMDA, MFDS, TGA, HSA, CDSCO), cloud/data residency cues, and pricing archetypes (license vs. pay per use).
  • 4. De risk pricing & deployment with Numbers in Context (OEM vs. pure play split, retrofit share, attach rate ladder) and Pulse Quick Actions for the next 12 months.
  • 5. Evidence & QA ready-every table and split passes a documented QA loop and cites the evidence stack used in the APAC model.

Snapshots & Takeaways

  • APAC growth arc: ~US$0.61B -> ~US$7.3B (2023-2032), ~31% CAGR; APAC's share of the global market nears 30% by 2032.
  • Where revenue concentrates: CT/MR remain the core; fastest unit scale comes from POCUS ultrasound and low bandwidth DR in India/ASEAN; PET/Nuclear grows off oncology theranostics.
  • Clinical engines: Oncology, Neurology (stroke), and Cardiology together deliver ~75% of absolute growth to 2032.
  • Shift in revenue mix: Hardware share declines as fleets modernize; Software + Cloud/Pay per Use expand fastest (enterprise suites in JP/KR/ANZ; pay per study in India/ASEAN).
  • Attach rate baseline: CT ~10% -> rising with OEM bundles; MR ~8%; DR ~6%; retrofit dominates incremental dollars as the installed base upgrades.
  • What to act on in 12 months: File top modules per market (NMPA/PMDA/MFDS/TGA/HSA/CDSCO), pre validate on local clouds (data residency), lead with AI recon + stroke triage (JP/KR/ANZ) and DR chest/echo AI pay per study (India/ASEAN).

Methodology & QA

Forecasts reconcile top down APAC totals to the global rollup and bottom up attach rate flows by modality (shipments, installed base upgrades, factory vs. retrofit attach, and local ASP bands). The APAC model is anchored by regulatory lines NMPA / PMDA / MFDS / TGA / HAS / CDSCO), ABDM digital health rails for India, and peer reviewed RWE. A four point QA loop checks reconciliation variance (Less than or equal to 0.5%), regulatory count deltas, evidence freshness, and ASP sanity for each country/modality.

TABLE OF CONTENTS

SECTION 1 - EXECUTIVE SUMMARY

  • The 25-second Read
  • Size & Pace (Who Contributes What by 2032)
  • Where Growth Concentrates
  • Country/Cluster Snapshots
  • APAC Watchlist (What to Act on in the Next 12 months)
  • Pulse Quick Actions (12 Months)

SECTION 2 - RESEARCH METHODOLOGY

  • Objective
  • Dual-lens Architecture
  • APAC-specific Evidence & Inputs
  • Model Calibration Choices (APAC)
  • Limitations & Mitigations (APAC)
  • Quality Assurance Loop

SECTION 3 - ASIA-PACIFIC (APAC) MARKET

  • Size, Trajectory & Strategic Importance
  • Demand Drivers & Headwinds
  • Competitive & Partnership Landscape
  • Strategic Clustering & Go-to-Market Nuances
  • Strategic Recommendations
  • Regulatory / Policy (What's New or Clarified)
  • AI Imaging Market by Country - APAC
  • Markintel GTM Growth and Maturity Matrix - APAC
    • Competitive Data Set - APAC
    • Numbers-in-Context - APAC
    • Strategic Takeaways - APAC
    • Growth & Maturity Highlights - APAC
  • M&A Watchlist - APAC
  • Regulatory Velocity - APAC
  • OEM AI Attach Rate - APAC
    • Attach-Rate Trends - APAC
    • Factory vs Retrofit Attach
  • GTM at-a-Glance - APAC
    • GTM Readiness Radar - APAC
    • Tiered Customer Landscape - APAC
    • GTM Timeline - APAC
    • Adjacency Opportunity Matrix - APAC
    • Country-Cluster Framework - APAC
    • White Space Partner Framework - APAC
    • Regulatory Funding Heatmap - APAC
    • Channel x Pricing Matrix - APAC
  • Fast Strategic Cues - APAC

SECTION 4 - CHINESE MARKET

  • China - Market Overview & Strategic Summary (2023-2032)
    • Urban-Rural Duality Matters
  • Strategic Takeaways
  • Chinese Market Forecasts (2023-2032)
    • Chinese Market by Clinical Area (2023-2032)
    • Chinese Market by Modality (2023-2032)
    • Chinese Market by Revenue Stream (2023-2032)
    • Chinese Market by Clinical Application (2023-2032)
    • Chinese Market by End-Use Organization (2023-2032)
    • Chinese Market by AI Technology (2023-2032)
  • Markintel Growth Maturity Matrix - China AI in Medical Imaging
    • Executive Commentary
    • Cross-Quadrant Insights & Tactical Guidance
    • Priority Recommendations (next 18 months)
    • Competitive Dataset - China
  • Markintel Ecosystem Collaboration Matrix - China
    • Decoding the 2 x 2 and Turning it into Action
    • Three Rules for Winning the Collaboration Game
    • Quick hit Actions for BD teams (Next Two Quarters)
  • Markintel Solution Adoption and Growth Matrix - China
    • Translating the Matrix into Action
    • Execution Priorities by Function
    • "First 100-Days" Checklist
    • Metrics that Matter
    • Operating Roadmap Takeaway
  • GTM at a Glance - China
    • GTM Readiness Radar - China
    • Tiered Customer Landscape - China
    • GTM Timeline - China
    • Adjacency-Opportunity Radar - China
    • Regulatory Funding Heatmap - China
    • Channel x Pricing Matrix - China
    • White Space Partnership Matrix - China

SECTION 5 - JAPANESE MARKET

  • Market Overview & Strategic Summary: Japan
  • Strategic Outlook
  • Action Points
  • Japanese Market Forecasts (2023-2032)
    • Japanese Market by Clinical Area (2023-2032)
    • Japanese Market by Modality (2023-2032)
    • Japanese Market by Clinical Application (2023-2032)
    • Japanese Market by End-Use Organization (2023-2032)
    • Japanese Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - Japan
    • Turning the Matrix into an Operating Road Map for Japan (2024 28)
  • Markintel Ecosystem Collaboration Matrix - Japan
    • Turning the Matrix into an Operating Roadmap
    • Playbook Highlights by Quadrant
    • Risk Checkpoints & Mitigations
  • Go-to-Market (GTM) Playbook - Japan
    • GTM Readiness Radar - Japan
    • Tiered Customer Landscape - Japan
    • GTM Timeline - Japan
    • Adjacency Opportunity Radar - Japan
    • Regulatory Funding Heatmap - Japan
    • Channel x Pricing Matrix - Japan
    • White Space Partnership Matrix - Japan
    • Fast Strategic Cues

SECTION 6 - INDIAN MARKET

  • Market Overview & Analysis
  • Market Mechanics
  • Constraint Map
  • Competitive Temperature
  • Actionable Opportunities (2024-26 Window)
  • Go Forward Recommendations (by player type)
  • What Success Looks Like
  • Indian Market Forecasts (2023-2032)
    • Indian Market by Clinical Area (2023-2032)
    • Indian Market by Modality (2023-2032)
    • Indian Market by Revenue Stream (2023-2032)
    • Indian Market by Clinical Application (2023-2032)
    • Indian Market by End-Use Organization (2023-2032)
    • Indian Market by AI Technology (2023-2032)
  • Markintel Solution Adoption & Growth Matrix - India
    • Solution Classes and Action Cues
    • Strategic Interpretation & Operating Roadmap
    • One-Page Operating Checklist
  • Markintel Ecosystem Collaboration Matrix - India
    • Operating Roadmap: Leveraging India's Collaboration Matrix
    • Strategic Sequencing (2024 27)
    • Execution Tips
    • Key Metrics to Track
  • Competitive Landscape - India
    • Operating Roadmap
  • GTM at a Glance - India
    • GTM Readiness Radar - India
    • Tiered Customer Landscape - India
    • GTM Timeline - India
    • Adjacency-Opportunity Radar - India
    • Regulatory x Funding Heatmap - India
    • White-Space Partnership Matrix
    • Channel x Pricing Matrix
    • Fast Strategic Cues (Do This First)

SECTION 7 - SOUTH KOREAN MARKET

  • Market Summary & Overview: South Korea
    • Key Market Dynamics
    • Strategic Takeaways
    • Top 3 Recommendations
    • South Korea Market Context
  • South Korean Market Forecasts (2023-2032)
    • South Korean Market by Clinical Area (2023-2032)
    • South Korean Market by Modality (2023-2032)
    • South Korean Market by Revenue Stream (2023-2032)
    • South Korean Market by Clinical Application (2023-2032)
    • South Korean Market by End-Use Organization Type (2023-2032)
    • South Korean Market by AI Technology (2023-2032)
  • GTM at a Glance - South Korea
    • Six-Pillar GTM Readiness Radar - South Korea
    • Tiered Customer Landscape - South Korea
    • Five-Step GTM Timeline - South Korea
    • Adjacency-Opportunity Radar - South Korea
    • Regulatory x Funding Heatmap - South Korea
    • Whitespace Partnership Matrix - South Korea
    • Channel x Pricing Matrix - Typical 2025 Deals
    • Fast Strategic Cues

SECTION 8 - AUSTRALIAN MARKET

  • Market Overview & Analysis
  • Market Structure & Growth Drivers
  • Segment Hotspots (Qualitative Sizing)
  • Competitive Landscape
  • Strategic Implications & GTM Priorities
  • Action-Oriented Recommendations (Next 12 Months)
  • Australian Market Forecasts (2023-2032)
    • Australian Market by Clinical Area (2023-2032)
    • Australian Market by Modality (2023-2032)
    • Australian Market by Revenue Stream (2023-2032)
    • Australian Market by Clinical Application (2023-2032)
    • Australian Market by End-Use Organization (2023-2032)
    • Australian Market by AI Technology (2023-2032)
  • GTM at a Glance - Australia
    • GTM Readiness Radar - Australia
    • GTM Timeline - Australia
    • Adjacency-Opportunity Radar - Australia
    • Regulatory x Funding Heatmap

SECTION 9 - REST OF ASIA-PACIFIC (ROAPAC) MARKET

  • Market Overview & Analysis
    • Regional Clusters
    • Market Dynamics - What's Shaping Buying Decisions
    • Actionable Recommendations
    • Quick-Hit Opportunities by Cluster
    • What Success Looks Like
  • Rest of Asia-Pacific Market Forecasts (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032)
    • Strategic Insights
    • Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032)
    • Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032)
  • GTM at a Glance - ROAPAC
    • GTM Readiness Heatmap - ROAPAC Clusters
    • Five-Step GTM Roll Out Timeline (2024 2029) - Keyed to Clusters

List of Tables

  • Table 1: AI Imaging Market by Country - APAC (2023-2032, USD Mill)
  • Table 2: Chinese Market by Clinical Area (2023-2032, USD Million)
  • Table 3: Chinese Market by Modality (2023-2032, USD Million)
  • Table 4: Chinese Market by Revenue Stream (2023-2032, USD Million)
  • Table 5: Chinese Market by Clinical Application (2023-2032, USD Million)
  • Table 6: Chinese Market by End-Use Organization (2023-2032, USD Million)
  • Table 7: Chinese Market by AI Technology (2023-2032, USD Million)
  • Table 8: Japanese Market by Clinical Area (2023-2032, USD Million)
  • Table 9: Japanese Market by Modality (2023-2032, USD Million)
  • Table 10: Japanese Market by Revenue Stream (2023-2032, USD Million)
  • Table 11: Japanese Market by Clinical Application (2023-2032, USD Million)
  • Table 12: Japanese Market by End-Use Organization (2023-2032, USD Million)
  • Table 13: Japanese Market by AI Technology (2023-2032, USD Million)
  • Table 14: Indian Market by Clinical Area (2023-2032, USD Million)
  • Table 15: Indian Market by Modality (2023-2032, USD Million)
  • Table 16: Indian Market by Revenue Stream (2023-2032, USD Million)
  • Table 17: Indian Market by Clinical Application (2023-2032, USD Million)
  • Table 18: Indian Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million)
  • Table 19: Indian Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million)
  • Table 20: South Korean Market by Clinical Area (2023-2032, USD Million)
  • Table 21: South Korean Market by Modality (2023-2032, USD Million)
  • Table 22: South Korean Market by Revenue Stream (2023-2032, USD Million)
  • Table 23: South Korean Market by Clinical Application (2023-2032, USD Million)
  • Table 24: South Korean Market End-Use Organization Type (2023-2032, USD Million)
  • Table 25: South Korean Market by AI Technology (2023-2032, USD Million)
  • Table 26: Australian Market by Clinical Area (2023-2032, USD Million)
  • Table 27: Australian Market by Modality (2023-2032, USD Million)
  • Table 28: Australian Market by Revenue Stream (2023-2032, USD Million)
  • Table 29:Australian Market by Clinical Application (2023-2032, USD Million)
  • Table 30: Australian Market by End-Use Organization (2023-2032, USD Million)
  • Table 31: Australian Market by AI Technology (2023-2032, USD Million)
  • Table 32: Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032, USD Million)
  • Table 33: Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032, USD Million)
  • Table 34: Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032, USD Million)
  • Table 35: Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032, USD Million)
  • Table 36: Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032, USD Million)
  • Table 37: Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032, USD Million)

List of Figures

  • Figure 1: APAC Top-Down Funnel - Country Group Mix (2023 vs 2032)
  • Figure 2: Bottom-up Attach Rate Flow APAC (Illustrative)
  • Figure 3: APAC Evidence -- Markintel Regional Model
  • Figure 4: Markintel GTM Growth and Maturity Matrix - APAC
  • Figure 5: Regulatory Velocity - APAC
  • Figure 6: OEM AI Attach Rate - APAC
  • Figure 7: AI Revenue Split - Factory vs Retrofi t - APAC
  • Figure 8: GTM Readiness Radar - APAC
  • Figure 9: Tiered Customer Landscape - APAC (2032)
  • Figure 10: GTM Timeline - APAC (2024-29)
  • Figure 11: Regulatory Funding Heatmap - APAC
  • Figure 12: Markintel Growth Maturity Matrix - China AI in Medical Imaging
  • Figure 13: Markintel Ecosystem Collaboration Matrix - China
  • Figure 14: Markintel Solution Adoption and Growth Matrix - China
  • Figure 15: GTM Readiness Radar - China
  • Figure 16: Tiered Customer Landscape - China (2032)
  • Figure 17: GTM Timeline - China (2024-29)
  • Figure 18: Adjacency-Opportunity Radar - China
  • Figure 19: Regulatory Funding Heatmap - China
  • Figure 20: Markintel Solution Adoption & Growth Matrix - Japan
  • Figure 21: Markintel Ecosystem Collaboration Matrix - Japan
  • Figure 22: GTM Readiness Radar - Japan
  • Figure 23: GTM Timeline - Japan
  • Figure 24: Adjacency Opportunity Radar - Japan
  • Figure 25: Regulatory Funding Heatmap - Japan
  • Figure 26: White Space Partnership Matrix - Japan
  • Figure 27: Markintel Solution Adoption & Growth Matrix - India
  • Figure 28: Markintel Ecosystem Collaboration Matrix - India
  • Figure 29: GTM Readiness Radar - India
  • Figure 30: Tiered Customer Landscape - India
  • Figure 31: GTM Timeline - India
  • Figure 32: Adjacency-Opportunity Radar - India
  • Figure 33: Regulatory x Funding Heatmap - India
  • Figure 34: Six-Pillar GTM Readiness Radar - South Korea
  • Figure 35: Tiered Customer Landscape - South Korea
  • Figure 36: Five-Step GTM Timeline - South Korea
  • Figure 37: Adjacency-Opportunity Radar - South Korea
  • Figure 38: Regulatory x Funding Heatmap - South Korea
  • Figure 39: GTM Readiness Radar - Australia
  • Figure 40: GTM Timeline - Australia
  • Figure 41: Adjacency-Opportunity Radar - Australia
  • Figure 42: Regulatory x Funding Heatmap
  • Figure 43: GTM Readiness Heatmap - ROAPAC Clusters
  • Figure 44: Five-Step GTM Roll Out Timeline (2024 2029) - ROAPAC